Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis

Annals of the Rheumatic Diseases

Volumn 67, Issue 3, 2008, Pages 309-314

  Cespedes Cruz A ^a,m   Gutierrez Suarez R ^a,n   Pistorio, A ^a   Ravelli, A ^a   Loy, A ^a   Murray, K J ^b   Gertoni, V ^c   Wulffraat, N ^d   Oliveira, S ^a,o   Walsh, J ^e   Calvo Penades, I ^f   Alpigiani, M G ^a   Lahdenne, P ^g   Saad Magalhaes C ^a,p   Cortis, E ^h   Lepore, L ⁱ   Kimura, Y ^j   Wouters, C ^k   Martini, A ^a   Ruperto, N ^a,l  

^a G GASLINI INSTITUTE   (Italy)

^b PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^c ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e ROYAL ALEXANDRA HOSPITAL   (United Kingdom)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

ⁱ UNIVERSITY OF TRIESTE   (Italy)

^j HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^k UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^l UNIVERSITY OF GENOA   (Italy)

^m INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

ⁿ HOSPITAL GENERAL DE MÉXICO   (Mexico)

^o Instituto de Puericultura e Pediatria Martagao Gesteira   (Brazil)

^p SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

ADOLESCENT; ARTICLE; CHILD; CHILD CARE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; FUNCTIONAL STATUS; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME; WELLBEING;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; QUALITY OF LIFE; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 39549087440     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.075895     Document Type: Article

References (25)

1. Oliveira S, Ravelli A, Pistorio A, Castell E, Malattia C, Prieur AM, et al. Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: the Pediatric Rheumatology International Trials Organization multinational quality of life cohort study. Arthritis Rheum 2007;57:35-43.
2. Garcia-Munitis P, Bandeira M, Pistorio A, Magni-Manzoni S, Ruperto N, Schivo A, et al. Level of agreement between children, parents, and physicians in rating pain intensity in juvenile idiopathic arthritis. Arthritis Rheum 2006;55:177-83.
3. Gutierrez-Suarez R, Pistorio A, Cespedes CA, Norambuena X, Flato B, Rumba I, et al. Health-related quality of life of patients with juvenile idiopathic arthritis coming from 3 different geographic areas. The PRINTO multinational quality of life cohort study. Rheumatology 2007;46:314-20.
4. Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. N Engl J Med 1992;326:1043-9.
5. Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SKF, Falcini F, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004;50:2191-201.
6. Woo P, Southwood TR, Prieur AM, Doré CJ, Grainger J, David J, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000;43:1849-57.
7. Lovell DJ, Giannini EH, Reiff A, Cawkwell D, Silverman ED, Norton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9.
8. Ruperto N, Lovell DJ, Goodman S, Reiff A, Jung L, Nemcova D, et al. 48-week data from the study of adalimumab in children with juvenile rheumatoid arthritis (JRA). Ann Rheum Dis 2006;65(Suppl 11):56.
9. Ruperto N, Lovell DJ, Prieur AM, Paz E, Rubio Perez NE, Silva CA, et al. Efficacy and safety of abatacept in children and adolescents with active juvenile idiopathic arthritis (JIA). Ann Rheum Dis 2006;65(Suppl 11):248.
10. Ruperto N, Martini A. International research networks in pediatric rheumatology: the PRINTO perspective. Curr Opin Rheumatol 2004;16:566-70.
11. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
12. Ruperto N, Ravelli A, Falcini F, Lepore L, De Sanctis R, Zulian F, et al. Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Ann Rheum Dis 1998;57:38-41.
13. Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritides: Durban, 1997. J Rheumatol 1998;25:1991-4.
14. Martini A, Ruperto N, for the Paediatric Rheumatology International Trials Organization (PRINTO). Quality of life in juvenile idiopathic arthritis patients compared to healthy children. Clin Exp Rheumatol 2001;19(Suppl 23):S1-172.
15. Ruperto N, Ravelli A, Pistorio A, Malattia C, Cavuto S, Gado-West L, et al. Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology. Clin Exp Rheumatol 2001;19:S1-9.
16. Landgraf JM, Abetz L, Ware JE. The CHO user's manual. 1st edn. Boston: The Health Institute, New England Medical Center, 1996.
17. Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994;37:1761-9.
18. Moher D, Schulz KF, Altman DG. for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001;357:1191-4.
19. Huygen ACJ, Kuis W, Sinnema G. Psychological, behavioural, and social adjustment in children and adolescents with juvenile chronic arthritis. Ann Rheum Dis 2000;59:276-82.
20. Myones BL, Williams GF, Billings A, Miller JJ. Social environment in families of children with juvenile arthritis. Arthritis Care Res 1988;1:17-22.
21. Mathias SD, Colwell HH, Miller DP, Moreland LW, Buatti M, Wanke L. Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clin Ther 2000;22:128-39.
22. Strand V, Tugwell P, Bombardier C, Maetzel N, Crawford B, Dorrier C, et al. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis Rheum 1999;42:1870-8.
23. Strand V, Scott DL, Emery P, Kalden JR, Smolen JS, Cannon GW, et al. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol 2005;32:590-601.
24. Russell AS, Wallenstein GV, Li T, Martin M, Maclean R, Blaisdell B, et al. Abatacept improves both the physical and mental health of rheumatoid arthritis patients with inadequate response to methotrexate therapy. Ann Rheum Dis 2007;66:189-94.
25. Emery P, Kosinski M, Li T, Martin M, Williams GR, Becker JC, et al. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. J Rheumatol 2006;33:681-9.